scholarly journals Can somatic healthcare use predict whether patients with chronic conditions consider the cooperation of their care to be god? A longitudinal cohort study

2016 ◽  
Vol 16 (6) ◽  
pp. 137
Author(s):  
Aslak Steinsbek ◽  
Vibeke Berg Forås
Keyword(s):  
Cohort Study ◽  
Chronic Conditions ◽  
Longitudinal Cohort Study ◽  
Healthcare Use ◽  
Longitudinal Cohort

scholarly journals Association between prescription of hypnotics/anxiolytics and mortality in multimorbid and non-multimorbid patients: a longitudinal cohort study in primary care

BMJ Open ◽  
2019 ◽  
Vol 9 (12) ◽  
pp. e033545 ◽  
Author(s):  
Kristjan Linnet ◽  
Johann Agust Sigurdsson ◽  
Margret Olafia Tomasdottir ◽  
Emil Larus Sigurdsson ◽  
Larus Steinthor Gudmundsson
Keyword(s):  
Primary Care ◽  
Cohort Study ◽  
Chronic Conditions ◽  
Reference Group ◽  
Longitudinal Cohort Study ◽  
Dependent Manner ◽  
Longitudinal Cohort ◽  
Multimorbid Patients

ObjectivesTo assess the risk of mortality in primary care patients, multimorbid (≥2 chronic conditions) or not, prescribed hypnotics/anxiolytics.DesignA longitudinal cohort studySettingPrimary healthcare in the Reykjavik area.Participants114 084 individuals (aged 10–79 years, average 38.5, SD 18.4) contacting general practitioners during 2009–2012 (mortality follow-up to 31 December 2016). Of those, the reference group comprised 58 560 persons who were neither multimorbid nor had redeemed prescriptions for hypnotics/anxiolytics. Participants (16 108) redeeming prescriptions for hypnotics/anxiolytics on a regular basis for 3 consecutive years were considered as consistent, long-term users. They were subdivided into low-dose (1–300 defined daily doses (DDD)/3 years), medium-dose (301–1095 DDDs/3 years) and high-dose users (>1095 DDDs/3 years). All six groups taking these drugs were compared with the reference group.Main outcome measuresAll-cause mortality.ResultsHRs were calculated with the no multimorbidity—no drug group as a reference, using Cox proportional hazards regression model adjusting for age, sex and the number of chronic conditions (n=111 767), patients with cancer excluded. During follow-up, 516 358 person-years in total, 1926 persons died. Mean follow-up was 1685 days (4.6 years), range 1–1826 days (5.0 years). For all multimorbid patients who took no drugs the HR was 1.14 (95% CI 1.00 to 1.30) compared with those without multimorbidity. HRs in the non-multimorbid participants varied from 1.49 to 3.35 (95% CI ranging from 1.03 to 4.11) with increasing doses of hypnotics/anxiolytics, and correspondingly from 1.55 to 3.52 (1.18 to 4.29) in multimorbid patients.ConclusionsMortality increased in a dose-dependent manner among both multimorbid and non-multimorbid patients taking hypnotics/anxiolytics. This increase was clearly associated with prescribing of these drugs. Their use should be limited to the recommended period of 2–4 up to 6 weeks; long-term use may incur increased risk and should be re-examined.

scholarly journals Frailty transitions predict healthcare use and Medicare payments in older Mexican Americans: a longitudinal cohort study

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Chih-Ying Li ◽  
Soham Al Snih ◽  
Lin-Na Chou ◽  
Amol Karmarkar ◽  
Yong-Fang Kuo ◽  
...  
Keyword(s):  
Cohort Study ◽  
Mexican Americans ◽  
Longitudinal Cohort Study ◽  
Healthcare Use ◽  
Longitudinal Cohort

2453-PUB: Changes in Metabolic Syndrome and Diabetes Risk: A Nationwide Longitudinal Cohort Study

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2453-PUB
Author(s):  
MIN-KYUNG LEE ◽  
HYUK-SANG KWON ◽  
KI-HO SONG ◽  
JAE HYUK LEE
Keyword(s):  
Metabolic Syndrome ◽  
Cohort Study ◽  
Diabetes Risk ◽  
Longitudinal Cohort Study ◽  
Longitudinal Cohort
Sign in / Sign up

Export Citation Format

Share Document